Equity Profile

ADMA

ADMA Biologics, Inc.

Health CareBiotechnology$2.1B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

ADMA Biologics, Inc. is a biotechnology company focused on developing and commercializing specialty biologics for the treatment of immune deficiencies....

Key Metrics to Watch

Revenue Growth

Investors will be keen to see if ADMA can maintain or accelerate its revenue growth, which is crucial for its long-term viability.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge the company's financial health and operational efficiency.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ADMA Q2-2026 Earnings Preview

Context

Company Snapshot

ADMA Biologics, Inc. is a biotechnology company focused on developing and commercializing specialty biologics for the treatment of immune deficiencies. Operating in the Health Care sector, ADMA plays a crucial role in addressing unmet medical needs, particularly in the area of immunoglobulin therapies.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+30.88%

Avg Stock Reaction

+0.95%

Last Quarter Recap

In Q1-2026, ADMA reported an EPS of $0.19, which did not have an analyst estimate for comparison. The stock experienced a slight decline of 1.66% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for ADMA's upcoming earnings report are mixed due to the lack of analyst estimates and management guidance. Investors are looking for signs of growth and profitability.

Bull Case

If ADMA can show strong revenue growth and improved EPS, it may indicate a successful market strategy and increased demand for its products.

Bear Case

Conversely, if the company reports disappointing revenue or EPS figures, it could raise concerns about its market position and future growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue growth rate for the immunoglobulin therapies segment?

This will be critical in determining ADMA's market position and future growth potential.

What is the outlook for EPS in the upcoming quarters?

EPS guidance will help investors assess the company's profitability and operational efficiency moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating ADMA's potential for growth in the immunoglobulin market, especially given recent trends in demand for specialty biologics.

Supporting Evidence

ADMA has consistently beaten EPS estimates in the past, suggesting a potential for positive surprises.

The options market is pricing in a significant move, indicating that investors expect volatility and potential upside.

Key Risk

If revenue growth exceeds expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around ADMA's ability to grow its revenue and improve profitability in a competitive market.

Bull Confirmed If

Revenue growth of over 15% year-over-year would confirm the bull case.

Bear Confirmed If

A decline in revenue or EPS below previous quarters would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±26.94%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±26.9% while ADMA has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

61.6%

Calls (13K)P/C Ratio: 1.16Puts (800)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

97.01%

of float

Insider

1.85%

of float

Holders

474

institutions

Top Holders· as of Dec 2025

Blackrock Inc.
36,333,325 sh · $409.1M
15.64%
2.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ADMA beats expectations, history suggests the stock could rise by around 0.27%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await more clarity from management.

Miss

A miss could lead to a decline of approximately 3.59%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or market expansion efforts.
2Details on operational efficiencies that could impact profit margins.
3Insights into competitive pressures in the immunoglobulin market.
4Management's outlook on future revenue and EPS growth.
5Responses to any recent regulatory changes affecting the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

ADMA Biologics, Inc. is a biotechnology company focused on developing and commercializing specialty biologics for the treatment of immune deficiencies....

Key Metrics to Watch

Revenue Growth

Investors will be keen to see if ADMA can maintain or accelerate its revenue growth, which is crucial for its long-term viability.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge the company's financial health and operational efficiency.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ADMA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+30.88%

Avg Stock Reaction

+0.95%

Last Quarter Recap

In Q1-2026, ADMA reported an EPS of $0.19, which did not have an analyst estimate for comparison. The stock experienced a slight decline of 1.66% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for ADMA's upcoming earnings report are mixed due to the lack of analyst estimates and management guidance. Investors are looking for signs of growth and profitability.

Bull Case

If ADMA can show strong revenue growth and improved EPS, it may indicate a successful market strategy and increased demand for its products.

Bear Case

Conversely, if the company reports disappointing revenue or EPS figures, it could raise concerns about its market position and future growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue growth rate for the immunoglobulin therapies segment?

This will be critical in determining ADMA's market position and future growth potential.

What is the outlook for EPS in the upcoming quarters?

EPS guidance will help investors assess the company's profitability and operational efficiency moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating ADMA's potential for growth in the immunoglobulin market, especially given recent trends in demand for specialty biologics.

Supporting Evidence

ADMA has consistently beaten EPS estimates in the past, suggesting a potential for positive surprises.

The options market is pricing in a significant move, indicating that investors expect volatility and potential upside.

Key Risk

If revenue growth exceeds expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around ADMA's ability to grow its revenue and improve profitability in a competitive market.

Bull Confirmed If

Revenue growth of over 15% year-over-year would confirm the bull case.

Bear Confirmed If

A decline in revenue or EPS below previous quarters would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±26.94%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±26.9% while ADMA has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

61.6%

Calls (13K)P/C Ratio: 1.16Puts (800)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

97.01%

of float

Insider

1.85%

of float

Holders

474

institutions

Top Holders· as of Dec 2025

Blackrock Inc.
36,333,325 sh · $409.1M
15.64%
2.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ADMA beats expectations, history suggests the stock could rise by around 0.27%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await more clarity from management.

Miss

A miss could lead to a decline of approximately 3.59%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or market expansion efforts.
2Details on operational efficiencies that could impact profit margins.
3Insights into competitive pressures in the immunoglobulin market.
4Management's outlook on future revenue and EPS growth.
5Responses to any recent regulatory changes affecting the biotechnology sector.